Doxorubicin specifically promotes eIF2α phosphorylation, triggering ER stress and autophagy activation to enhance CRT and HMGB1 surface exposure, thereby boosting tumor immunogenicity [219, 220]. This evidence concerns the gene HMGB1 and neoplasm.